Canadian Consensus Recommendations for the Management of Operable Stage II/III Non-Small-Cell Lung Cancer: Results of a Modified Delphi Process-Reference-Cited by-同舟云学术

Canadian Consensus Recommendations for the Management of Operable Stage II/III Non-Small-Cell Lung Cancer: Results of a Modified Delphi Process

Published:2023-12-06 Issue:12 Volume:30 Page:10363-10384
ISSN:1718-7729
Container-title:Current Oncology
language:en
Short-container-title:Current Oncology

Author:

Tankel James¹,Spicer Jonathan¹^ORCID,Chu Quincy²,Fiset Pierre Olivier³^ORCID,Kidane Biniam⁴^ORCID,Leighl Natasha B.⁵,Joubert Philippe⁶^ORCID,Maziak Donna⁷,Palma David⁸,McGuire Anna⁹,Melosky Barbara¹⁰^ORCID,Snow Stephanie¹¹^ORCID,Bahig Houda¹²,Blais Normand¹³^ORCID

Affiliation:

1. Department of Thoracic Surgery, McGill University Health Center, Montreal, QC H3G 1A4, Canada

2. Department of Medical Oncology, Cross Cancer Institute, Edmonton, AB T6G 1Z2, Canada

3. Department of Pathology, McGill University Health Center, Montreal, QC H3G 1A4, Canada

4. Section of Thoracic Surgery, University of Manitoba & Cancer Care Manitoba, Winnipeg, MB R3A 1R9, Canada

5. Division of Medical Oncology, Princess Margaret Cancer Center, Toronto, ON M5G 2C4, Canada

6. Department of Pathology, Institut Universitaire de Cardiologie et de Pneumologie de Québec-Université, Laval, QC G1V 4G5, Canada

7. Department of Thoracic Surgery, Ottawa Hospital, Ottawa, ON K1Y 4E9, Canada

8. Department of Radiation Oncology, London Health Services Center, London, ON N6A 5A5, Canada

9. Department of Thoracic Surgery, Vancouver General Hospital, Vancouver, BC V5Z 1M9, Canada

10. Department of Medical Oncology, BCCA, Vancouver, BC V5Z 4E6, Canada

11. Department of Medical Oncology, Queen Elizabeth II Health Sciences Center, Halifax, NS B3H 3A7, Canada

12. Department of Radiation Oncology, Centre Hospitalier de l’Université de Montréal, Montreal, QC H2X 3E4, Canada

13. Department of Medical Oncology, Centre Hospitalier de l’Université de Montréal, Montreal, QC H2X 3E4, Canada

Abstract

The treatment paradigm for patients with stage II/III non-small-cell lung cancer (NSCLC) is rapidly evolving. We performed a modified Delphi process culminating at the Early-stage Lung cancer International eXpert Retreat (ELIXR23) meeting held in Montreal, Canada, in June 2023. Participants included medical and radiation oncologists, thoracic surgeons and pathologists from across Quebec. Statements relating to diagnosis and treatment paradigms in the preoperative, operative and postoperative time periods were generated and modified until all held a high level of consensus. These statements are aimed to help guide clinicians involved in the treatment of patients with stage II/III NSCLC.

Funder

AstraZeneca

Publisher

MDPI AG

Link

https://www.mdpi.com/1718-7729/30/12/755/pdf

Reference118 articles.

1. EGFR mutation incidence in non-small-cell lung cancer of adenocarcinoma histology: A systematic review and global map by ethnicity (mutMapII);Midha;Am. J. Cancer Res.,2015

2. Projected estimates of cancer in Canada in 2022;Brenner;Can. Med. Assoc. J.,2022

3. Precision Diagnosis and Treatment for Advanced Non-Small-Cell Lung Cancer;Reck;N. Engl. J. Med.,2017

4. National Lung Screening Trial Research Team (2011). Reduced lung-cancer mortality with low-dose computed tomographic screening. N. Engl. J. Med., 365, 395–409.

5. Analysis of stage and clinical/prognostic factors for lung cancer from SEER registries: AJCC staging and collaborative stage data collection system;Chen;Cancer,2014